Trials / Recruiting
RecruitingNCT06215976
The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Cairo University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the protective effect of metformin on nephrotoxicity of cisplatin in patients with bladder cancer. The main questions it aims to answer are: * To determine protective effect of metformin on structural and functional kidney injury caused by cisplatin in patients with bladder cancer. * To evaluate the safety of combining cisplatin and metformin on patients with bladder cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin Hydrochloride 500 MG | Metformin 500mg tablets twice daily |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2024-06-01
- Completion
- 2024-12-30
- First posted
- 2024-01-22
- Last updated
- 2024-08-20
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06215976. Inclusion in this directory is not an endorsement.